VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA

Clinical trials for VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA trials appear

Sign up with your email to follow new studies for VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug study aims to control rare genetic tumor disorder

Disease control Recruiting now

This study is testing how well the drug belzutifan works for controlling tumors in people with von Hippel-Lindau (VHL) syndrome, a rare genetic condition that causes tumors in multiple organs. Researchers will follow 100 patients in Brazil to see how effectively the drug shrinks …

Matched conditions: VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA

Phase: PHASE2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA

Get alerted when new VON HIPPEL LINDAU-DEFICIENT CLEAR CELL RENAL CELL CARCINOMA trials appear

New drug study aims to control rare genetic tumor disorder